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Ovarian carcinoma is the leading cause of death from gynecologic malignancy in the US. Factors such as the molecular
heterogeneity of ovarian tumors and frequent diagnosis at advanced stages hamper eﬀective disease treatment. There is growing
emphasis on the identiﬁcation and development of targeted therapies to disrupt molecular pathways in cancer. The epidermal
growth factor (EGF) receptor is one such protein target with potential utility in the management of ovarian cancer. This paper will
discuss contributions of EGF receptor activation to ovarian cancer pathogenesis and the status of EGF receptor inhibitors and EGF
receptor targeted therapies in ovarian cancer treatment.
1.Introduction
Ovarian carcinoma is the leading cause of death from
gynecologic malignancy, with an estimated 15520 deaths in
the USA in 2008 [1]. Ovarian cancer is a highly metastatic
disease that is rarely detected when disease is conﬁned to
the ovary (stage I) and 5-year survival is >90%. The great
majority of ovarian cancer patients are initially diagnosed
with disseminated intra-abdominal disease (stages III–IV)
and have a 5-year survival of <20% [2]. Clinically, ovarian
tumors often involve the ovary and omentum, with diﬀuse,
multifocal intraperitoneal metastases and malignant ascites
[2, 3]. The combined factorsof late diagnosis and the cellular
and molecular heterogeneity of ovarian cancers hamper
eﬀorts to eﬀectively treat this disease.
For many cancers, including those of the ovary, there
is growing emphasis on the identiﬁcation and development
of targeted therapies to disrupt speciﬁc molecular pathways
contributing to disease progression [4]. The epidermal
growth factor (EGF) receptor is one such molecular target.
The EGF receptor impinges on multiple key hallmarks of
cancer deﬁned by Hanahan and Weinberg [5] and the EGF
receptor is associated with a gene expression pattern unique
to invasive tumor cells [6]. Aberrant expression and activity
oftheEGFreceptorisgenerallyrecognized tohaveadeleteri-
ous impact on the clinical outcome of cancer patients which
has fueled development of targeted therapeutics (reviewed
in [7–12]). This paper will discuss potential contributions
of EGF receptor activation to ovarian cancer pathogenesis
and the status of EGF receptor inhibitors and EGF receptor
targeted therapies in ovarian cancer treatment.
2.The EGFReceptor inOvarianCancer
The EGF receptor is a member of the receptor tyrosine
kinase (RTK) family of growth factor receptors and the
founding member of the ErbB subfamily that includes four
proteins: ErbB1 (EGF receptor), ErbB2 (HER-2), ErbB3
(HER-3), and ErbB4 (HER-4). The ErbB receptors are single
membrane spanning proteins possessing intrinsic tyrosine
kinase catalytic activity. Ligand binding promotes EGF
receptor homo- and heterodimerization with ErbB family
members, activation of the intracellular tyrosine kinase
domain,andstimulationofnumerousdownstreamsignaling
cascades associated with cell growth and survival, increased
angiogenesis, and tumor metastasis (reviewed in [7–10],
[13–17]).
The most common form of ovarian cancer arises from
the ovarian surface epithelium (OSE). The OSE expresses
EGF receptors in vivo and EGF receptor activity is impli-
cated in gonad development, growth and diﬀerentiation
of the ovarian follicle, and postovulatory repair [18–20].2 Journal of Oncology
It has been proposed that EGF stimulation of the OSE
contributes to its rapid post-ovulatory proliferation and
to epithelial-mesenchymal transition (EMT) of OSE cells
within the ruptured follicle. Malfunctions in post-ovulatory
repair are believed to contribute to formation of epithelial
inclusion cysts, which are the preferential sites of malignant
transformation [15, 21, 22]. The normal OSE responds to
EGF receptor generated signals by displaying a phenotypic
plasticity characterized by transition between epithelial and
ﬁbroblastic phenotypes, a characteristic usually limited to
immature, regenerating, or neoplastic epithelia [23]. These
attributesoftheadultOSEsuggestthatthistissueis“primed”
to respond to the EGF receptor during tumor development
and progression.
In addition to its role in normal ovarian epithelium,
there is abundant evidence of aberrant EGF receptor
and/or ligand expression in ovarian cancer. A recent review
[15] provides an excellent and comprehensive summary
of immunohistochemical studies evaluating ErbB receptor
and ErbB ligand expression in malignant ovarian tumors.
Brieﬂy, published reports estimate EGF receptor expression
in 10–70 percent of human epithelial ovarian cancer cases
(reviewed in [15]). A smaller subset of studies has examined
ampliﬁcation of the EGF receptor gene in ovarian cancer. An
advantage of this approach is the relative stability of DNA in
archived samples, but because EGF receptor overexpression
can occur in the absence of gene ampliﬁcation, these studies
may underestimate the frequency of elevated EGF receptor
protein in tumors. Despite this caveat, EGF receptor gene
ampliﬁcationisdetectedin ∼10–20percentofovariancancer
cases [24–26], with low-level gains detected more frequently
in 43 percent of tumors [24]. Thus, based on detection of
protein or gene ampliﬁcation, there is strong evidence for
elevated EGF receptor expression in a signiﬁcant fraction of
ovarian cancer cases.
Overall, elevated EGF receptor is associated with less
favorable disease outcomes in a number of human tumors
[17, 27–29]. Despite evidence for EGF receptor expression
in ovarian tumors [15], studies on the relationships between
receptor and patient outcomes do not provide a uniform
pictureontheclinicalconsequencesofelevatedEGFreceptor
levels.Basedonstudieswithnormaltissuereferencecontrols,
elevated EGF receptor levels signiﬁcantly correlated with
aggressive disease characteristics [24] and high tumor EGF
receptor expression was proposed as the most signiﬁcant
prognostic factor for disease-free and overall survival [30].
An overall conclusion that aberrant EGF receptor status is
a factor in ovarian cancer outcome is supported by a meta-
analysis study revealing a relationship between EGF receptor
and decreased survival [31], and the abundant evidence
linking EGF receptor to poor patient outcome in other
cancers of epithelial origin.
3. Consequences of EGF Receptor Activation
inOvarianCancer
A limited number of studies examine activated (tyrosine
phosphorylated) EGF receptor in ovarian tumors and over-
all,littleattentionhasbeengiventoreceptoractivationstatus
and disease parameters. In one study, 11.8 percent of ovarian
tumors were positive for phosphorylated EGF receptor
(pEGFR) but no clinicopathological parameter or survival
diﬀerences were noted [32]. In another study, twenty-four
heavily pretreated patients with epithelial ovarian cancer
all had detectable EGF receptor and p-EGFR (Y1148),
suggesting that EGF receptor activation might be more
evident in advanced disease [33]. We conducted a tumor
tissue array analysis and found evidence for pEGFR in
approximately 1/3 of ovarian tumor samples [34]. EGF
receptor activation was statistically positively correlated with
matrix metalloproteinase (MMP)-9 expression, a protein
associated with tumor invasion and metastasis. Together,
these in vivo data indicate that activated EGF receptor is
present in ovarian tumor specimens, likely driving aspects of
tumor behavior.
The mitogenic eﬀects of EGF receptor activation in
ovarian tumor cells are well documented. EGF increases the
growth potential of primary ovarian surface epithelial (OSE)
cells in culture [35] and gene expression proﬁling of normal
rat ovarian surface epithelium following EGF treatment
demonstrates EGF-dependent activation of genes involved in
cell cycle and proliferation, apoptosis, and protein turnover
[36]. In addition, malignant transformation of rat OSE
cells results in alteration of downstream eﬀectors of the
EGF receptor pathway [36]. Regarding ovarian tumor cells,
numerous studies demonstrate that autocrine and paracrine
stimulation of the EGF receptor promotes ovarian tumor cell
growth(reviewedin[37,38]).Furthermore,blockadeofEGF
receptor activation or signaling inhibits ovarian tumor cell
growth in vitro and in vivo (reviewed in [37]).
In addition to fostering cell growth, activation of the
EGF receptor is associated with stimulation of metastasis-
associated cellular responses. Many aspects of tumor metas-
tasis resemble features of epithelial-mesenchymal transition
(EMT) [39–43]. Notably, EGF receptor activation is capable
of driving EMT-associated events in epithelial ovarian car-
cinoma cells in culture including migration and invasion,
disruption of E-cadherin-mediated intercellular junctions,
and production of matrix degrading proteinases (reviewed
in [37, 38, 44, 45]). In contrast to the well-deﬁned events
that characterize EMT in development, tumor-associated
EMT is currently viewed as a continuum of phenotypic
plasticity and gain of mesenchymal characteristics. Tumor
phenotype likely reﬂects the particular complement of EMT
regulatory factors expressed in cells or within the tumor
microenvironment [42–45]. The functional consequences of
this phenotypic plasticity are not fully understood, but may
play a role in modulation of cell survival in suspension
(ascites), chemoresistance, and intraperitoneal anchoring of
metastatic lesions (reviewed in [42, 44, 46]).
Based on the evidence that (1) ovarian tumors share
certain characteristics (EGF receptor overexpression and
activation) with tumors approved for treatment with EGF
receptor inhibitors, (2) receptor activation drives tumor-
relevant responses in ovarian tumor cells, and (3) ovarian
tumor growth is reduced by EGF receptor directed therapeu-
tics in preclinical models, the EGF receptor inhibitors haveJournal of Oncology 3
Table 1: FDA approved EGF receptor inhibitors.
Generic, brand
name Type Mechanism Clinical Dose
Range (route)
Approved
Tumors
Company
Geﬁtinib,
Iressa
ZD1839
Small molecule
TKI
Inhibits
intracellular
EGFR tyrosine
kinase
phosphorylation
250mg daily
(oral)
Platinum and
taxane resistant
nonsmall cell
lung cancer
Astra-Zeneca
Erlotinib,
Tarceva
OS-774
CP-358774
Small molecule
TKI
Inhibits
intracellular
EGFR tyrosine
kinase
phosphorylation
100mg–150mg
daily (oral)
Nonsmall cell
lung cancer,
pancreatic
cancer
OSI Pharmaceuticals/Genentech
Lapatinib,
TYKERB
GW 572016
Small molecule
dual TKI,
EGFR-1 and
EGFR-2,
Inhibits het-
erodimerization
and her1/her2
phosphorylation
1250mg daily
days 1–21 (oral)
Her2+breast
cancer
refractory to
herceptin and
chemo
Glaxo-Smith Kline
Cetuximab,
Erbitux
IMC-C225
Human/mouse
chimeric MAb
Extracellular
domain binding
and ligand
blockade
400mg/m2 load
then 250mg/m2
weekly (IV)
Metastatic
colorectal
cancer, head,
and neck
ImClone
Panitumamab,
Vectibix
ABX-EGF
Humanized
MAb
Extracellular
domain binding
and ligand
blockade
6mg/kgevery
14 days (IV)
Metastatic
refractory
colorectal
cancer
Amgen/Abgenix
moved forward into clinical trials for ovarian cancer and are
discussed in the following section.
4. ClinicalStatus of EGFReceptor Inhibition
inOvarianCancer
With the advent of better understanding of the molecular
mechanisms contributing to ovarian cancer, novel recep-
tor targeted therapeutics or “biologic therapeutics” either
administered alone or in combination with conventional
chemotherapy have become a rapidly developing strategy
in clinical trials design. Based on expression of the EGF
receptor in ovarian cancer and the known consequences of
receptor activation, this pathway could be a prime target
for therapeutic blockade [4]. Numerous anti-EGF receptor
agentsareunderactivedevelopmentandeachcompoundhas
subtle diﬀerences in target binding, downstream signaling,
ease of administration and toxicity proﬁles. Yet despite
favorable preclinical studies using EGF receptor antagonists,
clinical trial outcomes in ovarian cancer have been overall
disappointing. Investigations are underway to understand
the mechanism of escape from EGF receptor blockade as
well as to identify clinical predictors of antagonist response.
The following sections will summarize the success and
shortcomings of these agents in ovarian cancer trials.
The majority of EGF receptor inhibitor agents in clinical
trial development fall into two categories: small molecule
tyrosine kinase inhibitors (TKIs) that compete with ATP for
its binding site in the tyrosine kinase domain or monoclonal
antibodies (MAbs) against the extracellular domain that
interfere with ligand binding and/or receptor dimerization.
Additional EGF receptor directed therapeutic strategies
include development of EGF vaccines, receptor downreg-
ulation by antisense oligonucleotides [47]. EGF receptor
dependent targeting of imaging agents, chemotherapeutic
agents, and toxins will be discussed later in this paper.
A signiﬁcant clinical diﬀerence between the small
molecule TKIs and MAbs is that the TKIs are orally admin-
istered and require daily dosing (especially the reversible
inhibitors) to maintain target blockade whereas the MAbs
are given intraveneously usually weekly or every 2 weeks.
The TKIs and MAbs share a toxicity proﬁle which includes
fatigue, diarrhea, and a robust acneiform rash. The cuta-
neous rash has been described as a clinical indicator of EGF
receptor blockade due to abrogation of receptor signaling
in nontumor tissues such as the skin and gut mucosa [47].
In addition, hypersensitivity reactions are a concern with
MAbs, especially the nonhumanized or chimeric agents.
Several TKIs and MAbs are FDA approved for treatment of
speciﬁc solid tumors, yet none have performed well enough
in ovarian cancer trials to warrant such approval (Table 1).
Additional compounds are under clinical development in
ovarian cancer and other solid tumors (Table 2).
4.1. EGF Receptor Speciﬁc Inhibitors. In clinical trials EGF
receptor inhibitors have been administered as single agents
and in combination with chemotherapy. Generally the trials
are conducted in patients with recurrent ovarian cancer, and
often patients have been heavily pretreated before receiving
the targeted therapeutics. The common dosing schedules4 Journal of Oncology
Table 2: Non-FDA approved EGFR inhibitors. Data derived from the NCI Drug Dictionary and Clinical Trials Search http://
www.nci.nih.gov/Templates/drugdictionary and [4, 47].
Generic or
research
name
Type Mechanism
Clinical
trial-ovarian
cancer, other
Clinical dose
range (route) Company
CI-1033
PD 183805
Canertinib
Small molecule
TKI
Irreversible
binding to
ATP-binding
site EGFR 1, 2,
3, 4
Phase II
50mg–200 mg
daily day 1–21
(oral)
Pﬁzer
EKB-569
Pelitinib
Small molecule
TKI
Irreversible
binding to TK
domain of
EGFR 1, 2, 4
None, Phase I in
solid tumors
25mg daily
(oral) Wyeth-Ayerst
PKI-166 Small molecule
TKI
Reversible
binding to TKI
domain EGFR 1,
2
None, Phase I in
solid tumors
600mg–700mg
2w e e k so n / o ﬀ Novartis
AV-412
Second
generation dual
TKI
Reversible
binding to TKI
domain EGFR
1,2
None, active
Phase I trial in
solid tumors
Dose escalation
daily, dose
escalation three
times/wk
AVEO
Pharmaceuticals
BIBW-2992
Tovok
Second
generation dual
TKI
Irreversible
binding to TKI
domain EGFR 1,
2
None, Phase I in
solid tumors
and Phase II in
lung, breast,
cancer
50mg daily
(oral), 70mg
daily 2weeks
on/oﬀ
Boehringer
Ingelheim’s
CUDC-101 Small molecule
TKI
Multi-targeted
HDAC/EGFR 1,
2
None, Phase I
solid tumors
Dose escalation,
unknown
starting dose
Curis, Inc.
BMS-690154 Small molecule
TKI
Binds tyrosine
kinase domains
of EFGR1, 2 and
VEGFR-2
None, Phase I in
combo with
paclitaxel and
carboplatin
Dose escalation,
unknown
starting dose
Bristol-Myers
Squibb
Matuzumab,
EMD 72000 Humanized MAb
Extracellular
domain binding
and ligand
blockade
Phase II EGFR+,
other
head+neck,
lung, gastric
800mg weekly
(IV)
EMD
Serono/Merk
KGaA
Pertuzumab Humanized MAb
Extracellular
her2 ligand
blockade,
prevents dimers
with EGFR-1
Phase II, lung,
breast, prostate
840mg load
followed by
420mg every 3
weeks (IV)
Merck Serono
RO5083945 Glycoengineered
MAb
Binds to EGFR
extracellular
domain, inhibits
dimers
None, Phase I
EGFR+ solid
tumors
Dose escalation
start at 50mg
(IV)
Roche
Pharmaceuticals
from multiple Phase I trials for the oral TKIs are shown in
Table 1. Geﬁtinib alone (500mg) performed poorly in Phase
II trials with minimal clinical response for ovarian cancer
patients. The only responder had an activating mutation in
the EGF receptor catalytic domain similar to the mutations
evident in responsive lung cancer patients [48]. Erlotinib
alone (150mg) performed slightly better with 6% of the
patients responding based on tumor regression and 44% of
patients had stable disease [4]. Geﬁtinib has been combined
with cytotoxic chemotherapy such as carboplatin, pacli-
taxel, topotecan, oxaliplatin, vinorelbine, and the aromatase
inhibitor anastrazole in multiple Phases I and II trials with
some patients responding to treatment [4, 47]. Eroltinib has
been combined with carboplatin, docetaxel, paclitaxel, and
the VEGFR inhibitor bevacizumab [4]. Several of these trials
were performed as front line treatment after cytoreductive
surgery demonstrating good clinical and some pathologic
completeresponserates,buttheresponseratesdonotappear
dramaticallydiﬀerentwhencomparedtohistoriccontrolsfor
conventional therapy alone. The pipeline of EGF receptorJournal of Oncology 5
tyrosine kinase inhibitors continues to expand (Table 2). A
randomized Phase II trial of the irreversible EGF receptor
inhibitor CI-1033 was performed in a heavily pretreated
population of women with recurrent ovarian cancer. Two
diﬀerentoraldoseregimensweregiven(50mgversus200mg
daily) for 21 days. Unfortunately there were no responders to
single agent treatment and no association between baseline
ErbBexpressionanddiseasestability[49].Futurestudieswill
likelyseethesenewagentsincombinationwithcytotoxicand
other biologic agents.
There are many possible reasons to account for the mod-
est responses to EGF receptor inhibitors. The oral tyrosine
kinase inhibitors can be diﬃcult to use in this patient popu-
lation, as advanced disease causes loss of bowel function and
potential unreliable absorption of drug. Another signiﬁcant
concern is the lack of validated biomarkers for response to
these TKIs. To date, activating mutations in the EGF receptor
kinase domain are the only known predictors of response,
but these mutations have not been fully explored in ovarian
tumors.
The monoclonal antibodies against the EGF receptor
ligand binding domain have some pharmacologic advan-
tages and may perhaps lead to better clinical outcomes
compared to the TKIs. Cetuximab is the prototype MAb
and has been administered alone or in combination with
carboplatin +/− paclitaxel. A Gynecologic Oncology Group
(GOG) Phase II trial of cetuximab and carboplatin in
platinum sensitive recurrent ovarian cancer showed a 35%
response rate (partial and complete responses) in patients
with tumors displaying EGF receptor overexpression docu-
mented by immunohistochemistry (IHC). Of note, 93% of
patients had overexpression of EGF receptor in the primary
archived tumor as determined by immunohistochemistry
[50]. Although it is tempting to conclude that EGF receptor
immunohistochemical analysis of formalin ﬁxed, paraﬃn
embedded tissue is of predictive value for response rate,
this has been neither quantiﬁed nor validated. A Phase
II trial of EMD 72000 (matuzumab) given at 800mg IV
weekly enrolled 37 women with heavily pretreated platinum
resistant recurrent ovarian cancer. EGF receptor status was
not evaluated for entry criteria or for correlation to clinical
response and there were no objective responses in this
group when matuzumab was used as monotherapy [51].
The authors concluded that matuzumab monotherapy was
not eﬀective for this heavily pretreated group of women.
Panitumumab is a fully humanized EGFR MAb under active
investigation, particularly in lung and colorectal cancer. It is
expected to elicit fewer hypersensitivity reactions than the
chimeric human/mouse cetuximab, but to date, there is little
direct clinical trial emphasis in ovarian cancer.
4.2. Dual Receptor Inhibition. Dual inhibition of ErbB
receptor family members is an interesting approach for
targeted therapy as much of the signaling is generated by
heterodimers, particularly heterodimers of EGF receptor
and ErbB2. Lapatinib is an oral small molecule tyrosine
kinase inhibitor that reversibly inhibits both ErbB1 and
ErbB2. It is well tolerated alone and in combination with
chemotherapy as determined by Phase I trials [4, 47].
Our group recently completed a Phase I/II trial of weekly
metronomic carboplatin and paclitaxel in combination with
lapatinib (1250mg daily) in 25 evaluable patients with
recurrent ovarian cancer. Interval evaluation showed a 50%
response rate (complete and partial response) with the
expected gastrointestinal and hematologic toxicities [52].
The ﬁnal analysis and publication of this study is pending.
Canertinib (CI-1033) is a newer oral dual TKI which inhibits
autophosphorylation of all ErbB receptors including a highly
tumorigenic, constitutively active mutant form of the EGF
receptor (EGFRvIII) [47]. This agent showed no signiﬁcant
activity as a single agent in a Phase II study in patients with
recurrent ovarian cancer.
Monoclonal antibody dimerization inhibitors have
shown the most promise in preclinical studies. Per-
tuzumab is the prototype of this inhibitor class and pre-
vents ErbB2/HER2 dimerization with the EGF receptor,
ErbB3/HER3, and ErbB4/HER4 leading to inhibition of
MAP kinase and PI3 kinase signaling. A Phase II trial was
conducted by Gordon et al. that included 123 patients with
recurrent ovarian cancer (the majority platinum resistant).
Two diﬀerent dosing strategies of pertuzumab as a single
agent demonstrated an overall response rate of 4.3% and
a mean response duration of 18.6 weeks [53]. Only 28
patients had biopsy material accessible for evaluation of
phosphorylated HER2 (pHER2) status by ELISA. Of this
group only 8 patients had pHER2+ tissues with one patient
in this group experiencing a partial response. The 20 other
tumors did not show pHER2 expression and there were
no treatment responses in this group [53]. This suggests
that pHER2 rather than HER2 overexpression may be a
viablebiomarkerforresponsealthoughvalidationstudiesare
desperately needed. Two ongoing randomized Phase II trials
in relapsed ovarian cancer are evaluating pertuzumab versus
placebo in combination with gemcitabine or carboplatin
[54, 55]. In these trials treatments were tolerated, but clinical
response endpoints have not yet been reached. In an early
analysis of the data, low ErbB3/HER3 mRNA levels as
measured in 122 of the 130 patient archival tumor tissues
appeared to predict clinical beneﬁt in the cohort receiving
gemcitabine + pertuzumab versus the gemcitabine + placebo
group [54]. Final analyses of both pertuzamab trials are
pending. Additional monoclonal antibodies developed to
inhibit EGF receptor family members are listed in Table 2
and studies to test the toxicity and eﬃcacy of these agents
in ovarian cancer are needed.
5.EGFReceptor asa TargetingMolecule
for Imaging Agents and Therapeutics
In addition to therapies directed against the EGF receptor
as discussed previously, this receptor has been used to
deliver imaging agents or therapeutics to tumors. To target
the EGF receptor on tumor cells, EGF receptor ligands or
anti-EGF receptor MAbs are incorporated into complexes
containing a therapeutic or imaging agent. EGF receptor
ligands such as mouse EGF can be conjugated through
its N-terminus without aﬀecting receptor binding ability.
In contrast, human EGF has two additional amino groups6 Journal of Oncology
due to internal lysines, and their conjugation can interfere
with receptor binding [56]. For that reason mouse EGF
rather than human EGF is usually employed for EGF
receptor targeting. Novel peptides that speciﬁcally bind to
EGF receptor provide alternative targeting moieties. Such
peptides have been identiﬁed either through screening of
a virtual peptide library [57], or through screening phage
display libraries [58] for peptides that speciﬁcally bind to
the EGF receptor, including lysine-deﬁcient EGF variants
[56]. EGF receptor-targeting moieties are conjugated with
imaging or therapeutic agents such as radionuclides, cancer
chemotherapeutic agents, toxins, RNase, or photosenstiz-
ers. In addition, delivery of oligonucleotides or expression
vectors to either suppress or express certain genes in EGF
receptor-positive cells through the use of viral or nonviral
delivery systems has been reported. Recently more complex
systemshavebeendesignedthatemployvariousnanocarriers
as targeted delivery systems.
The simplest form of an EGF receptor-targeting complex
is radiolabelled-EGF, TKI inhibitor, anti-EGF receptor MAb,
or engineered anti-EGF receptor fragments, which can be
usedforinvivoimagingorfortherapeuticpurposes[59,60].
The targeted radionuclide delivery serves as a cytotoxic agent
by itself and has been employed in boron neutron capture
therapy [61, 62], although optimal therapeutic eﬀects may
not be achieved with stand alone boron therapy [63].
Radionuclides as imaging agents can be used to evaluate
whether tumors are EGF receptor positive and thus likely
to respond to EGF receptor-targeted therapies, or monitor
response to therapy. Imaging techniques used to detect
EGF receptor-expressing tumors in small animals include
positron emission tomography (PET), magnetic resonance
(MR), and single photon emission computed tomography
(SPECT) [59, 60, 64] .T h e s et e c h n i q u e si n v o l v ep o s i t r o n
emitting radionuclides (such as 11C, 18F, among others), beta
emitters(suchasTechnetium(99mTc)andLutetium(177Lu)),
gamma emitters (such as iodide (125I) and Indium (111In)),
and alpha emitters (such as astatine (211At) and bismuth
(212Bi, 213Bi)) [59, 60, 64, 65]. Numerous preclinical studies
indicate that tumor targeting can be achieved through the
EGF receptor; however, most of these studies did not include
ovarian tumor models.
In addition to radionuclides, cancer chemotherapeu-
tic agents such as cisplatin [66], doxorubicin [67, 68],
carminomycin [69], and tyrosine kinase inhibitors [70, 71]
have been delivered to EGF receptor-positive cells through
conjugation to EGF or to anti-EGF receptor mAb either
directly or through a polymer linker. Numerous toxin
conjugates that inhibit speciﬁc molecular targets within
the cell have been delivered to EGF receptor-positive cells
including pseudomonas exotoxin (PE) [72], amanitin [73],
gelonin [74], and ricin chain A [75–78]. Furthermore,
RNases targeted to the EGF receptor were cytotoxic to cancer
cells [79–83] and photosensitizers used for photodynamic
therapy have been successfully targeted to EGF receptor-
positive cells [84–87]. Phase I clinical trials for TP-38
which is a fusion of a mutated PE and the EGF receptor
ligand transforming growth alpha demonstrate that it is well
tolerated with promising clinical response in patients with
recurring malignant brain tumors [88]. The main challenges
to expanding use of these toxin conjugates in clinical trials
include reducing their immunogenicity by shielding the
toxin portion of the complex, and the need to improve
delivery to solid tumors [72].
EGF receptor targeted approaches have been used for
viral and nonviral gene delivery to cells. As an example
of viral systems, avidin-adenovirus (ADV) that expresses
GFP was functionalized with EGF, and GFP expression was
enhanced in EGF receptor-overexpressing cells compared
to cells that moderately express EGF receptor or relative
to naked or PEG-ADV [89]. DNA/polycation complexes
have been employed for eﬃcient gene delivery as nonviral
systems. EGF or anti-EGF receptor MAb was conjugated to
cationic polymers such as poly-L-lysine (PLL) [90–95]o r
polyethyleneimine(PEI)[96–102]thatarepositivelycharged
and thus interact with negatively charged oligonucleotides
or expression vectors. These systems eﬃciently transfected
tumor cells in a receptor-dependent fashion. A number of
strategies to improve EGF receptor-speciﬁc gene transfer
or speciﬁcity include PEG or poly–L-glutamic acid (PLG).
Other modiﬁcations that enhance EGF receptor gene trans-
fer include incorporation of melittin, a membrane active
peptide [103], or incorporation of PEG to reduce albumin-
caused aggregation [104] and protect the complexes from
serum proteins [105].
New generations of nanocarriers are under intense
investigation as they oﬀer advantages over administering
a drug alone or in a simple conjugated targeting moiety.
Nanocarriers have numerous beneﬁts including their ability
to deliver hydrophobic drugs, increased drug loading, the
potential to load multiple drugs or imaging agents, and the
abilitytofunctionalizenanocarrierswithmultiplemolecules.
Moreover, because of their size these nanocarriers can
passivelytargettumorsthroughtheenhancedretentioneﬀect
caused by large gaps between vascular endothelial cells tissue
and defective lymphatic drainage in tumor tissue [106].
In addition to passive targeting, active targeting of cancer
tissue can be achieved using nanocarriers functionalized
with a targeting moiety such as an EGF receptor ligand
or an anti-EGF receptor MAb. Several nanocarriers have
been employed as delivery vehicles for drugs or imaging
agents to target EGF receptor-positive cancers including
liposomes [107–112], gelatin nanoparticles [113, 114], gold
[115],dendrimers [116],andcarbonnanotubes[117].These
nanocarriers speciﬁcally bound to and were internalized by
EGF receptor-expressing cancer cells in vitro [109, 115, 116,
118], or preferentially accumulated at tumor sites in vivo
[107, 109, 113].
We successfully targeted carbon nanotubes functional-
ized with EGF and a PEG-ﬂuorescein conjugate to ovarian
tumor cells [118]. Speciﬁc EGF receptor targeting and
cellular uptake was achieved by coating the nanotubes with
PL-PEG2000. Furthermore, we ﬁnd that these vehicles were
traﬃcked to lysosomes, consistent with the fate of ligand-
activated EGF receptor (Zeineldin, unpublished data). Lyso-
somes provide an acidic environment that is conducive to
releaseofdrugsattachedtothedeliveryvehiclethroughacid-
labile linkers. This property may allow for the design ofJournal of Oncology 7
Table 3: Clinical trials combining the EGF receptor antagonists with other signaling pathway inhibitors.
American Society of Clinical Oncology (ASCO) 2009 Annual Meeting Proceedings
Phase I trial of bevacizumab + everolimus + panitumumab in refractory solid tumors [117]
Phase I trial of cetuximab and erlotinib in solid tumors [119]
Phase I trial of dasatinib + cetuximab in advanced solid tumors [120]
therapeutics that will release drugs intracellularly following
EGF receptor targeted internalization. In addition, nanocar-
r i e r sa r eb e i n gd e v e l o p e da se ﬃcient drug delivery systems to
improvethecellularuptakeofcertaintherapeuticagentssuch
as inhibitory RNA or to enhance the therapeutic eﬃcacy of
drugs [106]. A pioneering example of a targeted nanocarrier
that just completed phase I trials is CALAA-01. CALAA-01
is a stabilized cyclodextrin-containing polymer that delivers
inhibitory RNA through transferrin targeting (Calando
Pharmaceuticals:http://www.insertt.com).Itisexpectedthat
nanotechnologywillleadtoinnovativeplatformsfortargeted
drug delivery in future therapeutics.
6.SummaryandFuturePerspectives
There is abundant evidence that EGF receptor activation
drives cellular processes linked to ovarian tumor develop-
ment, tumor cell survival, and metastasis. However, the
overall clinical impact of targeting the EGF receptor and its
dimers in ovarian cancer, either by monoclonal antibodies or
inhibition of the tyrosine kinase domain, has been modest
in unselected women with advanced or recurrent ovarian
cancer. Although the EGF receptor is a genetically validated
target for non-small-cell lung cancer, therapeutic EGF
receptor inhibition results in signiﬁcant tumor regression in
only 10–20% of patients [121]. One key goal in applying
these agents to ovarian and other cancers will be to identify
patients most likely to beneﬁt from targeted therapies and
to validate biomarkers of response [2, 4]. This type of
preselection is standard in breast cancer, for example, where
the estrogen receptor status of a tumor plays a major role in
therapeutic decision-making strategy.
Clearly, a better understanding of in vivo eﬃcacy,
improved predictive biomarkers of response, and an under-
standing of the molecular “escape” pathways for EGF
receptor antagonists is needed in ovarian cancer. Given
concurrent activation of signaling pathways and pathway
crosstalk in tumor cells, inhibition of multiple pathways
has been proposed as a strategy to improve the impact of
targeted therapeutics [2]. Accordingly, the latest approach
in clinical trials is to combine the EGF receptor antagonists
with inhibitors of other related or downstream signaling
pathways. Phase I clinical trials in solid tumors have been
presented recently at the 2009 American Society of Clinical
Oncology (ASCO) meeting demonstrating this strategy
(Table 3). Agents such as the mTOR inhibitor everolimus
and vascular endothelial growth factor receptor inhibitor
bevicizumab have been combined with panitumumab, and
cetuximab has been combined with the BCR/ABL and src
tyrosine kinase inhibitor. Dose limiting toxicities are similar
as seen in other combined trials. The impact on biologic
endpoints in vivo will be critical to assess the mechanisms
of action of these combined therapies.
Ongoing research continues to identify new and more
eﬀective inhibitors of EGF receptor activity, and novel
approaches to target antitumor therapies via the EGF recep-
tor. Exploiting the EGF receptor to target and deliver drugs
orimagingagentstotumorcellsshowspromiseinpreclinical
models and an EGF receptor targeted toxin is in clinical
trials for glioblastoma [88]. There is resurgence of interest in
this strategy based on new generations of nanocarriers with
improved drug delivery characteristics and the potential to
deliver multiple drugs to tumor cells. Although application
of EGF receptor antagonists and EGF receptor targeted
therapies to ovarian cancer treatment lags behind that of
certain other tumors such as lung and colorectal cancers,
lessons learned in using these agents in other diseases are
likely to beneﬁt ovarian cancer patients in the future.
Acknowledgment
This work was supported by the National Institutes of Health
Award R01 CA109545.
References
[1] A. Jemal, R. Siegel, E. Ward, et al., “Cancer statistics, 2008,”
CA: Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96,
2008.
[2] R. C. Bast Jr., B. Hennessy, and G. B. Mills, “The biology
of ovarian cancer: new opportunities for translation,” Nature
Reviews Cancer, vol. 9, no. 6, pp. 415–428, 2009.
[3] R. Scully, R. Young, and P. Clement, “Tumors of the ovary,
maldeveloped gonads, fallopian tube, and broad ligament,”
in Atlas of Tumor Pathology,J .R o s i aa n dL .S o b i n ,E d s . ,v o l .
Fascicle 23, Armed Forces Institute of Pathlogy, Washington,
DC, USA, 1998.
[4] T. A. Yap, C. P. Carden, and S. B. Kaye, “Beyond chemother-
apy: targeted therapies in ovarian cancer,” Nature Reviews
Cancer, vol. 9, no. 3, pp. 167–181, 2009.
[5] D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,”
Cell, vol. 100, no. 1, pp. 57–70, 2000.
[6] J. Condeelis, R. H. Singer, and J. E. Segall, “The great
escape: when cancer cells hijack the genes for chemotaxis and
motility,” Annual Review of Cell and Developmental Biology,
vol. 21, pp. 695–718, 2005.
[ 7 ] M .J .W i e d u w i l ta n dM .M .M o a s s e r ,“ T h ee p i d e r m a lg r o w t h
factorreceptorfamily:biologydrivingtargetedtherapeutics,”
Cellular and Molecular Life Sciences, vol. 65, no. 10, pp. 1566–
1584, 2008.
[8] J. Mendelsohn and J. Baselga, “Epidermal growth factor
receptor targeting in cancer,” Seminars in Oncology, vol. 33,
no. 4, pp. 369–385, 2006.8 Journal of Oncology
[9] H. Zhang, A. Berezov, Q. Wang, et al., “ErbB receptors: from
oncogenes to targeted cancer therapies,” Journal of Clinical
Investigation, vol. 117, no. 8, pp. 2051–2058, 2007.
[10] E. M. Bublil and Y. Yarden, “The EGF receptor family: spear-
heading a merger of signaling and therapeutics,” Current
Opinion in Cell Biology, vol. 19, no. 2, pp. 124–134, 2007.
[11] J. B. Johnston, S. Navaratnam, M. W. Pitz, et al., “Targeting
the EGFR pathway for cancer therapy,” Current Medicinal
Chemistry, vol. 13, no. 29, pp. 3483–3492, 2006.
[12] F. Ciardiello and G. Tortora, “EGFR antagonists in cancer
treatment,” The New England Journal of Medicine, vol. 358,
no. 11, pp. 1160–1174, 2008.
[13] B. Linggi and G. Carpenter, “ErbB receptors: new insights on
mechanisms and biology,” Trends in Cell Biology, vol. 16, no.
12, pp. 649–656, 2006.
[14] A. Citri and Y. Yarden, “EGF-ERBB signalling: towards the
systems level,” Nature Reviews Molecular Cell Biology, vol. 7,
no. 7, pp. 505–516, 2006.
[15] J. M. Lafky, J. A. Wilken, A. T. Baron, and N. J. Maihle,
“Clinical implications of the ErbB/epidermal growth factor
(EGF) receptor family and its ligands in ovarian cancer,”
Biochimica et Biophysica Acta, vol. 1785, no. 2, pp. 232–265,
2008.
[16] N. Normanno, A. De Luca, C. Bianco, et al., “Epidermal
growth factor receptor (EGFR) signaling in cancer,” Gene,
vol. 366, no. 1, pp. 2–16, 2006.
[17] M. Sibilia, R. Kroismayr, B. M. Lichtenberger, A. Natarajan,
M. Hecking, and M. Holcmann, “The epidermal growth
factor receptor: from development to tumorigenesis,” Diﬀer-
entiation, vol. 75, no. 9, pp. 770–787, 2007.
[18] N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang,
and P. C. K. Leung, “Ovarian surface epithelium: biology,
endocrinology, and pathology,” Endocrine Reviews, vol. 22,
no. 2, pp. 255–288, 2001.
[19] M. Conti, M. Hsieh, J.-Y. Park, and Y.-Q. Su, “Role of
the epidermal growth factor network in ovarian follicles,”
Molecular Endocrinology, vol. 20, no. 4, pp. 715–723, 2006.
[20] I. Ben-Ami, S. Freimann, L. Armon, A. Dantes, R. Ron-El,
and A. Amsterdam, “Novel function of ovarian growth fac-
tors: combined studies by DNA microarray, biochemical and
physiological approaches,” Molecular Human Reproduction,
vol. 12, no. 7, pp. 413–419, 2006.
[21] K. C. Choi and N. Auersperg, “The ovarian surface epithe-
lium: simple source of a complex disease,” Minerva Gineco-
logica, vol. 55, no. 4, pp. 297–314, 2003.
[22] H. Naora, “The heterogeneity of epithelial ovarian cancers:
reconciling old and new paradigms,” Expert Reviews in
Molecular Medicine, vol. 9, no. 13, pp. 1–12, 2007.
[23] A. S. Wong and N. Auersperg, “Normal ovarian surface
epithelium.,” Cancer Treatment and Research, vol. 107, pp.
161–183, 2002.
[24] H. Lassus, H. Sihto, A. Leminen, et al., “Gene ampliﬁcation,
mutation, and protein expression of EGFR and mutations of
ERBB2 in serous ovarian carcinoma,” J o u r n a lo fM o l e c u l a r
Medicine, vol. 84, no. 8, pp. 671–681, 2006.
[25] S. Stadlmann, U. Gueth, U. Reiser, et al., “Epithelial growth
factor receptor status in primary and recurrent ovarian
cancer,” Modern Pathology, vol. 19, no. 4, pp. 607–610, 2006.
[26] I. Dimova, B. Zaharieva, S. Raitcheva, R. Dimitrov, N.
Doganov, and D. Toncheva, “Tissue microarray analysis of
EGFR and erbB2 copy number changes in ovarian tumors,”
International Journal of Gynecological Cancer, vol. 16, no. 1,
pp. 145–151, 2006.
[27] I. Amit, R. Wides, and Y. Yarden, “Evolvable signaling net-
works of receptor tyrosine kinases: relevance of robustness
to malignancy and to cancer therapy,” Molecular Systems
Biology, vol. 3, p. 151, 2007.
[28] R. Zandi, A. B. Larsen, P. Andersen, M.-T. Stockhausen, and
H. S. Poulsen, “Mechanisms for oncogenic activation of the
epidermalgrowthfactorreceptor,”CellularSignalling,vol.19,
no. 10, pp. 2013–2023, 2007.
[29] D. J. Riese II, R. M. Gallo, and J. Settleman, “Mutational
activation of ErbB family receptor tyrosine kinases: insights
into mechanisms of signal transduction and tumorigenesis,”
BioEssays, vol. 29, no. 6, pp. 558–565, 2007.
[ 3 0 ] A .P s yrri ,M .K a s s a r ,Z .Y u ,e ta l . ,“ E ﬀect of epidermal growth
factor receptor expression level on survival in patients with
epithelial ovarian cancer,” Clinical Cancer Research, vol. 11,
no. 24, pp. 8637–8643, 2005.
[31] A. P. G. Crijns, H. M. Boezen, J. P. Schouten, et al.,
“Prognostic factors in ovarian cancer: current evidence and
future prospects,” European Journal of Cancer, Supplement,
vol. 1, no. 6, pp. 127–145, 2003, ECCO 12 Education Book.
[32] P. de Graeﬀ, A. P. G. Crijns, K. A. Ten Hoor, et al., “The ErbB
signalling pathway: protein expression and prognostic value
inepithelialovariancancer,”BritishJournalofCancer,vol.99,
no. 2, pp. 341–349, 2008.
[33] E. M. Posadas, M. S. Liel, V. Kwitkowski, et al., “A phase
II and pharmacodynamic study of geﬁtinib in patients with
refractoryorrecurrentepithelialovariancancer,”Cancer,vol.
109, no. 7, pp. 1323–1330, 2007.
[34] K. D. Cowden Dahl, J. Symowicz, Y. Ning, et al., “Matrix
metalloproteinase9isamediatorofepidermalgrowthfactor-
dependent E-cadherin loss in ovarian carcinoma cells,”
Cancer Research, vol. 68, no. 12, pp. 4606–4613, 2008.
[35] C. H. Siemens and N. Auersperg, “Serial propagation of
human ovarian surface epithelium in tissue culture,” Journal
of Cellular Physiology, vol. 134, no. 3, pp. 347–356, 1988.
[36] A. Abdollahi, B. N. Gruver, C. Patriotis, and T. C. Hamilton,
“Identiﬁcation of epidermal growth factor-responsive genes
in normal rat ovarian surface epithelial cells,” Biochemical
and Biophysical Research Communications, vol. 307, no. 1, pp.
188–197, 2003.
[37] L. G. Hudson, R. Zeineldin, M. Silberberg, and M. S.
Stack,“Activatedepidermalgrowthfactorreceptorinovarian
cancer,” Cancer Treatment and Research. In press.
[38] M. V. Barbolina, N. M. Moss, S. D. Westfall, et al., “Microen-
vironmental regulation of ovarian cancer metastasis,” Cancer
Treatment and Research. In press.
[39] E. D. Hay, “EMT concept and examples from the vertebrate
embryo,” in Rise and Fall of Epithelial Phenotype: Concepts of
Epithelial-Mesenchymal Transition, P. Savagner, Ed., pp. 111–
134, Springer, Berlin, Germany, 2005.
[40] M. A. Huber, N. Kraut, and H. Beug, “Molecular require-
ments for epithelial-mesenchymal transition during tumor
progression,” Current Opinion in Cell Biology, vol. 17, no. 5,
pp. 548–558, 2005.
[41] V. L. Van Marck and M. E. Bracke, “Epithelial-mesenchymal
transitions in human cancer,” in Rise and Fall of Epithelial
Phenotype: Concepts of Epithelial-Mesenchymal Transition,P .
Savagner, Ed., pp. 111–134, Springer, Berlin, Germany, 2005.
[42] M. Guarino, B. Rubino, and G. Ballabio, “The role of
epithelial-mesenchymal transition in cancer pathology,”
Pathology, vol. 39, no. 3, pp. 305–318, 2007.Journal of Oncology 9
[43] J. C. Tse and R. Kalluri, “Mechanisms of metastasis:
epithelial-to-mesenchymal transition and contribution of
tumor microenvironment,” Journal of Cellular Biochemistry,
vol. 101, no. 4, pp. 816–829, 2007.
[44] L. G. Hudson, R. Zeineldin, and M. S. Stack, “Phenotypic
plasticity of neoplastic ovarian epithelium: unique cadherin
proﬁles in tumor progression,” Clinical and Experimental
Metastasis, vol. 25, no. 6, pp. 643–655, 2008.
[45] L. G. Hudson, N. M. Moss, and M. S. Stack, “Epidermal
growth factor receptor regulation of matrix metallopro-
teinases in epithelial ovarian carcinoma future,” Oncology
Reviews. In press.
[46] M. Sabbah, S. Emami, G. Redeuilh, et al., “Molecular
signature and therapeutic perspective of the epithelial-to-
mesenchymal transitions in epithelial cancers,” Drug Resis-
tance Updates, vol. 11, no. 4-5, pp. 123–151, 2008.
[47] M. J. Palayekar and T. J. Herzog, “The emerging role
of epidermal growth factor receptor inhibitors in ovarian
cancer,” InternationalJournalofGynecologicalCancer,vol.18,
no. 5, pp. 879–890, 2008.
[48] R. J. Schilder, M. W. Sill, R. B. Lee, et al., “Phase II evaluation
of imatinib mesylate in the treatment of recurrent or per-
sistent epithelial ovarian or primary peritoneal carcinoma:
a gynecologic oncology group study,” Journal of Clinical
Oncology, vol. 26, no. 20, pp. 3418–3425, 2008.
[49] S. Campos, O. Hamid, M. V. Seiden, et al., “Multicenter, ran-
domized phase II trial of oral CI-1033 for previously treated
advanced ovarian cancer,” Journal of Clinical Oncology, vol.
23, no. 24, pp. 5597–5604, 2005.
[ 5 0 ]A .A .S e c o r d ,J .A .B l e s s i n g ,D .K .A r m s t r o n g ,e ta l . ,“ P h a s e
II trial of cetuximab and carboplatin in relapsed platinum-
sensitive ovarian cancer and evaluation of epidermal growth
factor receptor expression: a gynecologic oncology group
study,” Gynecologic Oncology, vol. 108, pp. 493–499, 2008.
[51] M. V. Seiden, H. A. Burris, U. Matulonis, et al., “A phase II
trial of EMD72000 (matuzumab), a humanized anti-EGFR
monoclonal antibody, in patients with platinum-resistant
ovarian and primary peritoneal malignancies,” Gynecologic
Oncology, vol. 104, no. 3, pp. 727–731, 2007.
[52] S. E. Rivkin, C. Muller, D. Iriarte, J. Arthur, A. Canoy, and
H. Reid, “Phase I/II lapatinib plus Carboplatin and paclitaxel
in stage III or IV relapsed ovarian cancer patients,” Journal of
Clinical Oncology, vol. 26, supplement, p. 5556, 2008.
[53] M. S. Gordon, D. Matei, C. Aghajanian, et al., “Clinical
activity of pertuzumab (rhuMAb 2C4), a HER dimerization
inhibitor, in advanced ovarian cancer: potential predictive
relationship with tumor HER2 activation status,” Journal
of Clinical Oncology, vol. 24, no. 26, pp. 4324–4332, 2006,
Erratum in Journal of Clinical Oncology, vol. 26, no. 16, p.
2793, 2008.
[54] L. Amler, S. Makhija, T. Januario, et al., “Downregulation of
HER3 may predict clinical beneﬁts in ovarian cancer from
pertuzumab, a HER2 dimerization-inhibiting antibody,” in
Proceedings of the Annual Meeting of the American Society of
Clinical Oncology (ASCO ’08), 2008, abstract 25.
[55] S. B. Kaye, C. J. Poole, M. Bidzinksi, et al., “A randomized
phase II study evaluating the combination of Carboplatin-
based chemotherapy with pertuzumab (P) vs. Carboplatin-
based therapy alone in patients with relapsed, platinum
sensitiveovariancancer,”JournalofClinicalOncology,vol.26,
supplement, p. 5520, 2008.
[56] M. Bach, P. Holig, E. Schlosser, et al., “Isolation from phage
display libraries of lysine-deﬁcient human epidermal growth
factor variants for directional conjugation as targeting lig-
ands,” Protein Engineering, vol. 16, no. 12, pp. 1107–1113,
2003.
[57] S. Song, D. Liu, J. Peng, et al., “Novel peptide ligand directs
liposomestowardEGF-Rhigh-expressingcancercellsinvitro
and in vivo,” The FASEB Journal, vol. 23, pp. 1396–1404,
2009.
[58] Z. Li, R. Zhao, X. Wu, et al., “Identiﬁcation and characteri-
zation of a novel peptide ligand of epidermal growth factor
receptor for targeted delivery of therapeutics,” The FASEB
Journal, vol. 19, no. 14, pp. 1978–1985, 2005.
[59] M. A. Pantaleo, M. Nannini, A. Maleddu, et al., “Experimen-
tal results and related clinical implications of PET detection
of epidermal growth factor receptor (EGFr) in cancer,”
Annals of Oncology, vol. 20, no. 2, pp. 213–226, 2009.
[60] J. Carlsson, Z. P. Ren, K. Wester, et al., “Planning for
intracavitary anti-EGFR radionuclide therapy of gliomas.
Literature review and data on EGFR expression,” Journal of
Neuro-Oncology, vol. 77, no. 1, pp. 33–45, 2006.
[61] P. Olsson, L. Gedda, H. Goike, et al., “Uptake of a
b o r o n a t e de p i d e r m a lg r o w t hf a c t o r - d e x t r a nc o n j u g a t ei n
CHO xenografts with and without human EGF-receptor
expression,” Anti-Cancer Drug Design, vol. 13, no. 4, pp. 279–
289, 1998.
[62] R. F. Barth, W. Yang, and J. A. Coderre, “Rat brain tumor
models to assess the eﬃcacy of boron neutron capture
therapy:acriticalevaluation,”JournalofNeuro-Oncology,vol.
62, no. 1-2, pp. 61–74, 2003.
[63] W. Yang, R. F. Barth, G. Wu, W. Tjarks, P. Binns, and K. Riley,
“Boron neutron capture therapy of EGFR or EGFRvIII posi-
tive gliomas using either boronated monoclonal antibodies
or epidermal growth factor as molecular targeting agents,”
Applied Radiation and Isotopes, vol. 67, no. 7-8, pp. S328–
S331, 2009.
[64] W. Cai, G. Niu, and X. Chen, “Multimodality imaging of
the HER-kinase axis in cancer,” European Journal of Nuclear
Medicine and Molecular Imaging, vol. 35, no. 1, pp. 186–208,
2008.
[65] A. A. Rosenkranz, G. Vaidyanathan, O. R. Pozzi, V. G. Lunin,
M. R. Zalutsky, and A. S. Sobolev, “Engineered modular
recombinant transporters: application of new platform for
targeted radiotherapeutic agents to alpha-particle emitting
211 At,” International Journal of Radiation Oncology Biology
Physics, vol. 72, no. 1, pp. 193–200, 2008.
[66] B. Schechter, R. Arnon, M. Wilchek, et al., “Indirect
immunotargeting of cis-Pt to human epidermoid carcinoma
KB using the avidin-biotin system,” International Journal of
Cancer, vol. 48, no. 2, pp. 167–172, 1991.
[67] S. V. Lutsenko, N. B. Feldman, and S. E. Severin, “Cytotoxic
and antitumor activities of doxorubicin conjugates with the
epidermal growth factor and its receptor-binding fragment,”
Journal of Drug Targeting, vol. 10, no. 7, pp. 567–571, 2002.
[68] J. Vega, S. Ke, Z. Fan, S. Wallace, C. Charsangavej, and C. Li,
“Targeting doxorubicin to epidermal growth factor receptors
by site-speciﬁc conjugation of C225 to poly(L-glutamic
acid) through a polyethylene glycol spacer,” Pharmaceutical
Research, vol. 20, no. 5, pp. 826–832, 2003.
[ 6 9 ]S .V .L u t s e n k o ,N .B .F e l d m a n ,G .V .F i n a k o v a ,e ta l . ,
“Antitumor activity of alpha fetoprotein and epidermal
growthfactorconjugatesinvitroandinvivo,”TumorBiology,
vol. 21, no. 6, pp. 367–374, 2000.
[70] F. M. Uckun, R. K. Narla, X. Jun, et al., “Cytotoxic activity
of epidermal growth factor-genistein against breast cancer10 Journal of Oncology
cells,” Clinical Cancer Research, vol. 4, no. 4, pp. 901–912,
1998.
[71] F. M. Uckun, R. K. Narla, T. Zeren, et al., “In vivo toxicity,
pharmacokinetics,andanticanceractivityofGenisteinlinked
to recombinant human epidermal growth factor,” Clinical
Cancer Research, vol. 4, no. 5, pp. 1125–1134, 1998.
[72] I. Pastan, R. Hassan, D. J. FitzGerald, and R. J. Kreitman,
“Immunotoxin therapy of cancer,” Nature Reviews Cancer,
vol. 6, no. 7, pp. 559–565, 2006.
[73] U. Bermbach and H. Faulstich, “Epidermal growth factor
labeled β-amanitin-poly-L-ornithine: preparation and evi-
dence for speciﬁc cytotoxicity,” Biochemistry, vol. 29, no. 29,
pp. 6839–6845, 1990.
[74] N. Hirota, M. Ueda, S. Ozawa, O. Abe, and N. Shimizu,
“Suppression of an epidermal growth factor receptor-
hyperproducing tumor by an immunotoxin conjugate of
gelonin and a monoclonal anti-epidermal growth factor
receptor antibody,” Cancer Research, vol. 49, no. 24, part 1,
pp. 7106–7109, 1989.
[75] D. B. Cawley, H. R. Herschman, D. G. Gilliland, and R. J.
Collier, “Epidermal growth factor-toxin A chain conjugates:
EGF-ricin A is a potent toxin while EGF-diphtheria fragment
Ai sn o n t o x i c , ”Cell, vol. 22, no. 2, pp. 563–570, 1980.
[76] H. Masui, H. Kamrath, G. Apell, L. L. Houston, and
J. Mendelsohn, “Cytotoxicity against human tumor cells
mediated by the conjugate of anti-epidermal growth factor
receptormonoclonalantibodytorecombinantricinAchain,”
Cancer Research, vol. 49, no. 13, pp. 3482–3488, 1989.
[77] D. L. Simpson, D. B. Cawley, and H. R. Herschman, “Killing
of cultured hepatocytes by conjugates of asialofetuin and
EGF linked to the A chains of ricin or diphtheria toxin,” Cell,
vol. 29, no. 2, pp. 469–473, 1982.
[ 7 8 ]R .T a e t l e ,J .M .H o n e y s e t t ,a n dL .L .H o u s t o n ,“ E ﬀects of
anti-epidermal growth factor (EGF) receptor antibodies and
an anti-EGF receptor recombinant-Ricin A chain immuno-
conjugate on growth of human cells,” Journal of the National
Cancer Institute, vol. 80, no. 13, pp. 1053–1059, 1988.
[79] H.Jinno,M.Ueda,S.Ozawa,etal.,“Epidermalgrowthfactor
receptor-dependent cytotoxic eﬀect by an EGF-ribonuclease
conjugate on human cancer cell lines: a trial for less
immunogenic chimeric toxin,” Cancer Chemotherapy and
Pharmacology, vol. 38, no. 4, pp. 303–308, 1996.
[80] T. Suwa, M. Ueda, H. Jinno, et al., “Epidermal growth factor
receptor-dependent cytotoxic eﬀect of anti-EGFR antibody-
ribonuclease conjugate on human cancer cells,” Anticancer
Research, vol. 19, no. 5, pp. 4161–4165, 1999.
[81] S. Hoshimoto, M. Ueda, H. Jinno, M. Kitajima, J. Futami,
and M. Seno, “Mechanisms of the growth-inhibitory eﬀectof
the RNase-EGF fused protein against EGFR-overexpressing
cells,” Anticancer Research, vol. 26, no. 2, pp. 857–863, 2006.
[82] H. Jinno, M. Ueda, S. Ozawa, et al., “The cytotoxicity of a
conjugate composed of human epidermal growth factor and
eosinophil cationic protein,” Anticancer Research, vol. 22, no.
6, pp. 4141–4145, 2002.
[83] M. Ueda, K. Psarras, H. Jinno, et al., “Molecular targeting for
e p i d e r m a lg r o w t hf a c t o rr e c e p t o re x p r e s s e do nb r e a s tc a n c e r
cells by human fusion protein,” Breast Cancer, vol. 4, no. 4,
pp. 253–255, 1997.
[84] A. Gijsens and P. de Witte, “Photocytotoxic action of EGF-
PVA-Sn(IV)chlorin e6 and EGF-dextran-Sn(IV)chlorin e6
internalizableconjugatesonA431cells,”InternationalJournal
of Oncology, vol. 13, no. 6, pp. 1171–1177, 1998.
[85] A. Gijsens, L. Missiaen, W. Merlevede, and P. de Witte,
“Epidermal growth factor-mediated targeting of chlorin e6
selectively potentiates its photodynamic activity,” Cancer
Research, vol. 60, no. 8, pp. 2197–2202, 2000.
[ 8 6 ]S .V .L u t s e n k o ,N .B .F e l d m a n ,G .V .F i n a k o v a ,e ta l . ,
“Targeting phthalocyanines to tumor cells using epidermal
growth factor conjugates,” Tumor Biology, vol. 20, no. 4, pp.
218–224, 1999.
[87] A. A. Savitsky, N. V. Gukasova, S. G. Gumanov, et al., “Cyto-
toxic action of conjugates of α-fetoprotein and epidermal
growth factor with photoheme, chlorines, and phthalocya-
nines,” Biochemistry, vol. 65, no. 6, pp. 732–736, 2000.
[88] J. H. Sampson, G. Akabani, G. E. Archer, et al., “Intracerebral
infusion of an EGFR-targeted toxin in recurrent malignant
brain tumors,” Neuro-Oncology, vol. 10, no. 3, pp. 320–329,
2008.
[ 8 9 ] J .W .P a r k ,H .M o k ,a n dT .G .P a r k ,“ E p i d e r m a lgr o wt hf a c t o r
(EGF) receptor targeted delivery of PEGylated adenovirus,”
Biochemical and Biophysical Research Communications, vol.
366, no. 3, pp. 769–774, 2008.
[90] J. Chen, S. Gamou, A. Takayanagi, Y. Ohtake, M. Ohtsubo,
and N. Shimizu, “Targeted in vivo delivery of therapeutic
geneintoexperimentalsquamouscellcarcinomasusinganti-
epidermal growth factor receptor antibody: immunogene
approach,” Human Gene Therapy, vol. 9, no. 18, pp. 2673–
2681, 1998.
[91] R. J. Cristiano, “Epidermal growth factor mediated DNA
deliveryintolungcancercellsviatheepidermalgrowthfactor
receptor,” Cancer Gene Therapy, vol. 3, no. 1, pp. 4–10, 1996.
[92] Y. Ohtake, J. Chen, S. Gamou, et al., “Ex vivo delivery of
suicide genes into melanoma cells using epidermal growth
factor receptor-speciﬁc Fab immunogene,” Japanese Journal
of Cancer Research, vol. 90, no. 4, pp. 460–468, 1999.
[93] B. Xu, S. Wiehle, J. A. Roth, and R. J. Cristiano, “The
contribution of poly-L-lysine, epidermal growth factor and
streptavidin to EGF/PLL/DNA polyplex formation,” Gene
Therapy, vol. 5, no. 9, pp. 1235–1243, 1998.
[94] J. Chen, S. Gamou, A. Takayanagi, and N. Shimizu, “A
novel gene delivery system using EGF receptor-mediated
endocytosis,” FEBS Letters, vol. 338, no. 2, pp. 167–169, 1994.
[95] N. Shimizu, J. Chen, S. Gamou, and A. Takayanagi,
“Immunogene approach toward cancer therapy using ery-
throcyte growth factor receptor-mediated gene delivery,”
Cancer Gene Therapy, vol. 3, no. 2, pp. 113–120, 1996.
[96] A. Bonsted, E. Wagner, L. Prasmickaite, A. Hogset, and K.
Berg, “Photochemical enhancement of DNA delivery by EGF
receptor targeted polyplexes,” Methods in Molecular Biology,
vol. 434, pp. 171–181, 2008.
[97] J. Kloeckner, L. Prasmickaite, A. Hogset, K. Berg, and
E. Wagner, “Photochemically enhanced gene delivery of
EGF receptor-targeted DNA polyplexes,” Journal of Drug
Targeting, vol. 12, no. 4, pp. 205–213, 2004.
[98] Z. Li, R. Zhao, X. Wu, et al., “Identiﬁcation and characteri-
zation of a novel peptide ligand of epidermal growth factor
receptor for targeted delivery of therapeutics,” The FASEB
Journal, vol. 19, no. 14, pp. 1978–1985, 2005.
[99] T.Blessing,M.Kursa,R.Holzhauser,R.Kircheis,andE.Wag-
ner, “Diﬀerent strategies for formation of PEGylated EGF-
conjugated PEI/DNA complexes for targeted gene delivery,”
Bioconjugate Chemistry, vol. 12, no. 4, pp. 529–537, 2001.
[100] M. F. Wolschek, C. Thallinger, M. Kursa, et al., “Speciﬁc
systemic nonviral gene delivery to human hepatocellular
carcinoma xenografts in SCID mice,” Hepatology, vol. 36, no.
5, pp. 1106–1114, 2002.Journal of Oncology 11
[101] J. Kloeckner, S. Boeckle, D. Persson, et al., “DNA polyplexes
based on degradable oligoethylenimine-derivatives: combi-
nation with EGF receptor targeting and endosomal release
functions,” Journal of Controlled Release, vol. 116, no. 2, pp.
115–122, 2006.
[102] H. Lee, T. H. Kim, and T. G. Park, “A receptor-mediated gene
delivery system using streptavidin and biotin-derivatized,
p e g y l a t e de p i d e r m a lg r o w t hf a c t o r , ”Journal of Controlled
Release, vol. 83, no. 1, pp. 109–119, 2002.
[103] S. Boeckle, J. Fahrmeir, W. Roedl, M. Ogris, and E. Wagner,
“Melittin analogs with high lytic activity at endosomal pH
enhance transfection with puriﬁed targeted PEI polyplexes,”
Journal of Controlled Release, vol. 112, no. 2, pp. 240–248,
2006.
[104] Y. Koyama, T. Ito, H. Matsumoto, et al., “Novel poly(ethylene
glycol) derivatives with carboxylic acid pendant groups:
synthesis and their protection and enhancing eﬀect on
non-viral gene transfection systems,” Journal of Biomaterials
Science, Polymer Edition, vol. 14, no. 6, pp. 515–531, 2003.
[105] Y. Sun, Y. Tang, M. Chu, S. Song, and Y. Xin, “A convenient
and adjustable surface-modiﬁed complex containing poly-
L-glutamic acid conjugatesas a vector for gene delivery,”
International Journal of Nanomedicine, vol. 3, no. 2, pp. 249–
256, 2008.
[106] O. C. Farokhzad and R. Langer, “Impact of nanotechnology
on drug delivery,” ACS Nano, vol. 3, no. 1, pp. 16–20, 2009.
[107] S. Song, D. Liu, J. Peng, et al., “Peptide ligand-mediated
liposome distribution and targeting to EGFR expressing
tumor in vivo,” International Journal of Pharmaceutics, vol.
363, no. 1-2, pp. 155–161, 2008.
[108] J. Beuttler, M. Rothdiener, D. Muller, F. Y. Frejd, and R. E.
Kontermann, “Targeting of epidermal growth factor receptor
(EGFR)-expressing tumor cells with sterically stabilized
aﬃbody liposomes (SAL),” Bioconjugate Chemistry, vol. 20,
no. 6, pp. 1201–1208, 2009.
[109] S. Song, D. Liu, J. Peng, et al., “Novel peptide ligand directs
liposomestowardEGF-Rhigh-expressingcancercellsinvitro
and in vivo,” The FASEB Journal, vol. 23, no. 5, pp. 1396–
1404, 2009.
[110] E. Bohl Kullberg, N. Bergstrand, J. Carlsson, et al., “Devel-
opment of EGF-conjugated liposomes for targeted delivery
of boronated DNA-binding agents,” Bioconjugate Chemistry,
vol. 13, no. 4, pp. 737–743, 2002.
[111] E.B.Kullberg,M.Nestor,andL.Gedda,“Tumor-celltargeted
epidermal growth factor liposomes loaded with boronated
acridine: uptake and processing,” Pharmaceutical Research,
vol. 20, no. 2, pp. 229–236, 2003.
[112] E. B. Kullberg, Q. Wei, J. Capala, V. Giusti, P.-U. Malm-
strom, and L. Gedda, “EGF-receptor targeted liposomes
with boronated acridine: growth inhibition of cultured
glioma cells after neutron irradiation,” International Journal
of Radiation Biology, vol. 81, no. 8, pp. 621–629, 2005.
[113] C.-L. Tseng, W.-Y. Su, K.-C. Yen, K.-C. Yang, and F.-H. Lin,
“The use of biotinylated-EGF-modiﬁed gelatin nanoparticle
carrier to enhance cisplatin accumulation in cancerous lungs
via inhalation,” Biomaterials, vol. 30, no. 20, pp. 3476–3485,
2009.
[114] C.-L. Tseng, S. Y.-H. Wu, W.-H. Wang, et al., “Targeting eﬃ-
ciency and biodistribution of biotinylated-EGF-conjugated
gelatin nanoparticles administered via aerosol delivery in
nude mice with lung cancer,” Biomaterials, vol. 29, no. 20,
pp. 3014–3022, 2008.
[115] N. Nitin, D. J. Javier, and R. Richards-Kortum, “Oligo-
nucleotide-coated metallic nanoparticles as a ﬂexible plat-
form for molecular imaging agents,” Bioconjugate Chemistry,
vol. 18, no. 6, pp. 2090–2096, 2007.
[116] T. P. Thomas, R. Shukla, A. Kotlyar, et al., “Dendrimer-
epidermal growth factor conjugate displays superagonist
activity,” Biomacromolecules, vol. 9, no. 2, pp. 603–609, 2008.
[117] L. A. Howard, K. E. Bullock, J. C. Bendell, et al., “Beva-
cizumab (B) plus everolimus (E) and panitumumab (P)
in refractory advanced solid tumors,” in Proceedings of the
Annual Meeting of the American Society of Clinical Oncology
(ASCO ’09), 2009, abstract 3551.
[118] R. Zeineldin, M. Al-Haik, and L. G. Hudson, “Role of
polyethylene glycol integrity in speciﬁc receptor targeting of
carbon nanotubes to cancer cells,” Nano Letters, vol. 9, no. 2,
pp. 751–757, 2009.
[119] R. Sangha, C. Ho, L. Beckett, et al., “Dual epidermal
growth factor receptor (EGFR) inhibition: phase I study
combining cetuximab (C225) and erlotinib (E) in advanced
solid tumors,” in Proceedings of the Annual Meeting of the
American Society of Clinical Oncology (ASCO ’09), 2009,
abstract 3552.
[120] T. M. Feinstein, S. Agrawal, R. G. Stoller, M. J. Egorin,
and A. Argiris, “Phase I and pharmacokinetic (PK) study
of dasatinib (D) and cetuximab (C) in patients (pts) with
advanced solid malignancies,” in Proceedings of the Annual
Meeting of the American Society of Clinical Oncology (ASCO
’09), 2009, abstract 3540.
[121] J. D. Benson, Y.-N. P. Chen, S. A. Cornell-Kennon, et al.,
“Validating cancer drug targets,” Nature, vol. 441, no. 7092,
pp. 451–456, 2006.